4SC 203

Drug Profile

4SC 203

Alternative Names: 4SC-203; SC71710

Latest Information Update: 09 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4SC; ProQinase
  • Developer 4SC
  • Class Antineoplastics; Inositol phosphates; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 14 May 2013 Discontinued - Phase-I for Acute myeloid leukaemia (in volunteers) in Germany (IV)
  • 14 May 2013 Discontinued - Preclinical for Solid tumours in Germany (IV)
  • 07 Jan 2011 Preclinical trials in Solid tumours in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top